Skip to main content
SpringerLink
Log in

Antidementiva

  • Chapter
Arzneiverordnungs-Report 2004

Zusammenfassung

Cholinesterasehemmer haben nach einem erneuten kräftigen Verordnungszuwachs einen Anteil von 10% am Verordnungsvolumen der Antidementiva nach definierten Tagesdosen erreicht. Die Verordnungen des NMDA-Antagonisten Memantin nahmen dagegen leicht ab. Ginkgoextrakte sind weiter rückläufig, bleiben abertrotz ungenügender Beleglage die führende Präparategruppe mit über 50 % der Verordnungen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • AD2000 Collaborative Group (2004): Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 363: 2105–2115.

    Article  Google Scholar 

  • Areosa SA, Sherriff F (2003): Memantine for dementia. Cochrane Database Syst Rev 3: CD003154.

    Google Scholar 

  • Arzneimittelkommission der Deutschen Ärzteschaft (2001): Empfehlungen zur Therapie der Demenz. Arzneiverordnung in der Praxis, Sonderheft, 2. Auflage.

    Google Scholar 

  • Bickel H (2001): Demenzen im höheren Lebensalter: Schätzungen des Vorkommens und der Versorgungskosten. Z Gerontol Geriat 34: 108–115.

    Article  CAS  Google Scholar 

  • Birks J, Grimley EV, Van Dongen M (2002): Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev (4): CD003120.

    Google Scholar 

  • Birks J, Iakovidou V, Tsolaki M (2000): Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev 2: CD001191.

    Google Scholar 

  • Birks JS, Melzer D, Beppu H (2002): Donepezil for mild and moderate Alzheimer’s disease (Cochrane-Review). The Cochrane Library, Issue 2, 2002, Oxford: Updated Software.

    Google Scholar 

  • Birmingham K, Frantz S (2002): Set back to Alzheimer vaccine studies. Nature Med 8: 199–200.

    PubMed  CAS  Google Scholar 

  • Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller HJ, Rogers SL, Friedhoff LT and the International Donepezil Study Group (1999): The effects of donepezil in Alzheimer’s disease — results from a multinational trial. Dement Geriatr Cogn Disord 10: 237–244.

    Article  PubMed  CAS  Google Scholar 

  • Committee for Proprietary Medicinal Products (CPMP) (1998): Note for guidance on medicinal products in the treatment of Alzheimer’s disease.

    Google Scholar 

  • Corey-Bloom J, Anand R, Veach J for the ENA 713 B352 Study Group (1998): A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1: 55–65.

    CAS  Google Scholar 

  • Croisile B, Trillet M, Fondarai J, Laurent B, Mauguiere F, Billardon M (1993): Long-term and high-dose piracetam treatment of Alzheimer’s disease. Neurology 43: 301–305.

    Article  PubMed  CAS  Google Scholar 

  • Cummings JL (2004): Alzheimer’s disease. N Engl J Med 351: 56–67.

    Article  PubMed  CAS  Google Scholar 

  • Davies P, Maloney AJ (1976): Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 2: 1403.

    Article  PubMed  CAS  Google Scholar 

  • Dodel RC, Hampel H, Du Y (2003): Immunotherapy for Alzheimer’s disease. Lancet Neurology 2: 215–220.

    Article  PubMed  CAS  Google Scholar 

  • Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L et al (2001): Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56: 1154–1166.

    Article  PubMed  CAS  Google Scholar 

  • Drew S, Davies E (2001): Effectiveness of Ginkgo biloba in treating tinnitus: double blind, placebo controlled trial. Brit Med J 322: 1–6.

    Article  Google Scholar 

  • Fioravanti M, Flicker L (2001): Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev 2001(4): CD003159.

    Google Scholar 

  • Food and Drug Administration (1989): Peripheral and Central Nervous System Drugs Advisory Committee Meeting, July 7, 1989. Rockville MD: Dept. of Health and Human Services, Public Health service 1989: 227.

    Google Scholar 

  • Forette F, Anand R, Gharabawi G (1999): A phase II study in Patients with Alzheimer’s disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®). Eur J Neurol 6: 423–429.

    Article  PubMed  CAS  Google Scholar 

  • Gaitz CM, Varner RV, Overall JE (1977): Pharmacotherapy for organic brain syndrome in late life. Evaluation of an ergot derivative vs placebo. Arch Gen Psychiatry 34: 839–845.

    Article  PubMed  CAS  Google Scholar 

  • Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR (2003): Donepezil is associated with delayed nursing home placement in patients with Alzheimer’s disease. J Am Geriatr Soc 51: 937–44.

    Article  PubMed  Google Scholar 

  • Hollister L, Gruber N (1996): Drug treatment of Alzheimer’s disease. Effects on caregiver burden and patient quality of life. Drugs Aging 8: 47–55.

    Article  PubMed  CAS  Google Scholar 

  • In’t Veld BA, Riutenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T et al (2001): Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 345: 1515–1521.

    Article  CAS  Google Scholar 

  • Kanowski S, Herrmann WM, Stephan K, Wierich W, Hörr R (1996): Proof of efficacy of the Ginkgo biloba special extract Egb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 29: 47–56.

    Article  PubMed  CAS  Google Scholar 

  • Kleijnen J, Knipschild P (1992): Ginkgo biloba. Lancet 340: 1136–1139.

    Article  PubMed  CAS  Google Scholar 

  • Kugler J, Oswald WD, Herzfeld U, Seus R, Pingel J, Welzel D (1978): Langzeittherapie altersbedingter Insuffizienzerscheinungen des Gehirns. Dtsch Med Wochenschr 103: 456–462.

    Article  PubMed  CAS  Google Scholar 

  • Lanctot KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, Einarson TR (2003): Efficacy and safety of Cholinesterase inhibitors in Alzheimer’s disease: a meta-analysis. Canad Med Ass J 169: 557–564.

    Google Scholar 

  • Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF (1997): A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 278: 1327–1332.

    Article  PubMed  Google Scholar 

  • Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST (2002): Cholinesterase inhibitor treatment alters the natural history of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 72: 310–14.

    Article  PubMed  CAS  Google Scholar 

  • Marin DB, Davis KL (1995): Experimental therapeutics. In: Bloom FE, Kupfer DJ (eds): Psychopharmacology: The fourth generation of progress. Raven Press Ltd, New York, pp 1417–1426.

    Google Scholar 

  • Matthews HP, Korbey J, Wilkinson DG Rowden J (2000): Donepezil in Alzheimer’s disease: eighteen month results from Southampton Memory Clinic. Int J Geriatr Psychiatry 15: 713–20.

    Article  PubMed  CAS  Google Scholar 

  • Mix JA, Crews WD Jr (2002): A double-blind, placebo-controlled, randomized trial of Ginkgo biloba exctract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings. Hum Psychopharmacol 17: 267–277.

    Article  PubMed  CAS  Google Scholar 

  • Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD for the „312“ Study Group (2001): A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57: 481–488.

    Article  PubMed  CAS  Google Scholar 

  • Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R et al (2000): Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA 283: 1007–1015.

    Article  PubMed  CAS  Google Scholar 

  • Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003): Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nature Med 9: 448–452.

    Article  PubMed  CAS  Google Scholar 

  • O’Brien JT, Ballard CG (2001): Drugs for Alzheimer’s disease. Brit Med J 323: 123–124.

    Article  CAS  Google Scholar 

  • Olin J, Schneider L (2002): Galantamine for Alzheimer’s disease (Cochrane Review). In: Cochrane Library, Issue 1, 2002 Oxford: Update Software.

    Google Scholar 

  • Orgogozo J-M, Rigaud A-S, Stöffler A, Möbius HJ, Forette F (2002): Efficacy and safety of memantine in patients with mild to moderate vascular dementia. A randomized, placebo-controlled trial (MMM 300). Stroke 33: 1834–1839.

    Article  PubMed  CAS  Google Scholar 

  • Raskind MA, Peskind ER, Wessel T, Yuan W and the Galantamine USA-1 Study Group (2000): A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 54: 2261–2268.

    Article  PubMed  CAS  Google Scholar 

  • Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ for the Memantine Study Group (2003): Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 348: 1333–1341.

    Article  PubMed  CAS  Google Scholar 

  • Reines SA, Block GA, Morris JC, Liu G, Nessly ML et al (2004): Rofecoxib. No effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology 62: 66–71.

    Article  PubMed  CAS  Google Scholar 

  • Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT and the Donepezil Study Group (1998): A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 50: 136–145.

    Article  PubMed  CAS  Google Scholar 

  • Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M et al for the Members of the Alzheimer’s Disease Cooperative Study (1997): A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med 336: 1216–1222.

    Article  PubMed  CAS  Google Scholar 

  • Schellenberg R, Todorova A, Wedekind W, Schober F, Dimpfel W (1997): Pathophysiology and psychopharmacology of dementia — a new study design. 2. Cyclan-delate treatment — a placebo-controlled double-blind clinical trial. Neuropsy-chobiology 35: 132–142.

    CAS  Google Scholar 

  • Schneider LS (2004): AD2000: donepezil in Alzheimer’s disease. Lancet 363: 2100–2101.

    Article  PubMed  Google Scholar 

  • Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB Ockene JK et al for the WHIMS Investigators (2003): Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 289: 2651–2662.

    Article  PubMed  CAS  Google Scholar 

  • Solomon PR, Adams F, Silver A, Zimmer J, DeVeaux R (2002): Ginkgo for memory enhancement: a randomized controlled trial. JAMA 288: 835–840.

    Article  PubMed  Google Scholar 

  • Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I for the Memantine Study Group (2004): Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. JAMA 291: 317–324.

    Article  PubMed  CAS  Google Scholar 

  • Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C et al (2000): A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 54: 2269–2276.

    Article  PubMed  CAS  Google Scholar 

  • Thompson TL II, Filley CM, Mitchell WD, Culig KM, LoVerde M, Byyny RL (1990): Lack of efficacy of hydergine in patients with Alzheimer’s disease. N Engl J Med 323: 445–448.

    Article  PubMed  Google Scholar 

  • Van Dongen MCJM, van Rossum E, Kessels AGH, Sielhorst HJG, Knipschild PG (2000): The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J. Am Ger Soc 48: 1183–1194.

    Google Scholar 

  • Vernon MW, Sorkin EM (1991): Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drugs Aging 1: 17–35.

    Article  PubMed  CAS  Google Scholar 

  • Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A et al and the Donepezil Nordic Study Group (2001): A 1-year, randomised, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57: 489–495.

    Article  PubMed  CAS  Google Scholar 

  • Winblad B, Poritis N (1999): Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriat Psychiatry 14: 135–146.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Prof. Dr. med. Ulrich Schwabe

Authors
  1. Prof. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schwabe, U. (2004). Antidementiva. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2004. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18513-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18513-7_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-21359-8

  • Online ISBN: 978-3-642-18513-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation